跳至主要内容
临床试验/ACTRN12618000877280
ACTRN12618000877280招募中1 期

Phase Ib randomised, placebo-controlled, double-blinded trial using Cimetidine to prevent the Oto-, Nephro- and neuro-toxicity of Cisplatin by OCT2 inhibition in patients undergoing chemoradiation for head and neck cancer

Associate Professor Michael Jameson0 个研究点目标入组 30 人开始时间: 2018年5月23日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
15 Years 至 o limit(—)
性别
All

入选标准

  • •pathologically-confirmed locally-advanced HNSCC for which concurrent chemoradiation using cisplatin 100mg/m2 every 3 weeks for 3 cycles is planned
  • •adequate baseline renal function (estimated glomerular filtration rate >60 ml/min)
  • •adequate baseline hepatic and bone marrow function;
  • •have signed written, informed consent

排除标准

  • •planned to receive platinum-based chemotherapy before or after radiation
  • •prior chemotherapy with cisplatin or platinum analogues
  • •existing hearing loss > 50 dB between 2000 and 8000 Hz, or hearing aids needed
  • •radiation treatment plan would result in a cochlear dose > 45 Gy in either ear
  • •allergic to cimetidine
  • •taking drugs that are substrates of OCT2 (organic cation transporter type 2) unless the medication can safely be omitted on each day of cisplatin and cimetidine administration
  • •taking medications with which cimetidine is known to have clinically-significant drug-drug interactions
  • •congenital or acquired long QT syndrome
  • •co-morbidities that would preclude cisplatin use, such as cardiac failure
  • •pregnant or breastfeeding.

研究者

发起方
Associate Professor Michael Jameson

相似试验